TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis.
The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the rationale for the use of tolebrutinib in MS and what are its advantages over other B-cell directed therapies? (0:13)
- What has the Phase 2b study taught us about the efficacy and safety of tolebrutinib in patients with MS? (1:17)
- Could you tell us a little about the subgroup analysis of patients with highly active relapsing MS? (2:18)
- On the basis of these findings, what will be the likely place of tolebrutinib in the treatment paradigm for MS? (3:27)
Disclosures: Anthony Traboulsee has received research grants from Roche, Sanofi Genzyme, and has personal fees from Biogen, Consortium of MS Centers, Sanofi Genzyme, Roche, Novartis, and Teva Neuroscience.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!